. 2022 Oct 7;10(4):299–314. doi: 10.5599/admet.1476

Table 2.

Experimental and predicted pK_a, log P and solubility of the study compounds

Model Drug	BCS Class	Type	pK_a	log P	Solubility [20-26]
Model Drug	BCS Class	Type	pK_a	log P	FaSSIF (pH 6.5) (μg/mL)	FeSSIF (pH 5.0) (μg/mL)
Amiodarone	II	B	10.24 ± 0.15^a	7.80^a	351	784
Celecoxib	II	A	9.38 ± 0.08^a	3.02^b	46.2	103.3
Clopidogrel bisulfate	II/IV	B	4.6^b	4.2^b	130	500
danazol	II	N	---	4.70 +/- 0.43^b	8.4	28.8
Fluoxetine hydrochloride	I	B	9.62^a	4.50^a	1380	1620
Furosemide	IV	AA	9.90 ± 0.04^a 3.53 ± 0.06^a	2.56^a	3201	684
Griseofulvin	II	N	---	2.20^a	23.4	29.2
Isoniazid	I	B	3.8^b	-0.52^b	> 60,000	> 60,000
Nefazodone HCl	II	BB	6.7^b 2.1^b	3.5^b	252	383
Nifedipine	II	N	---	3.17^a	14.4	46.1
Zidovudine	III	A	9.40 ± 0.01^a	0.13^a	>10,000	>10,000

Type: A - acid; AA - diprotic acid; B - base; BB - diprotic base; N - neutral

^a Ref. [18]

^b Ref. [19]